These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8537267)

  • 21. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
    Wickman PA; Black JA; Moland ES; Thomson KS
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2255-7. PubMed ID: 16723599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incomplete cross-resistance between ciprofloxacin and sparfloxacin in staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin.
    Brumfitt W; Hamilton-Miller JM
    J Antimicrob Chemother; 1993 Apr; 31(4):610-2. PubMed ID: 8390435
    [No Abstract]   [Full Text] [Related]  

  • 24. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temafloxacin: in vitro comparison with five other antibacterial agents.
    Digranes A; Hardardottir H; Bottolfsen KL
    Chemotherapy; 1991; 37(2):98-105. PubMed ID: 2032475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
    Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
    J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
    Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R
    J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative activity of three new fluoroquinolones.
    Coll R; Esteve M; Moros M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):152-3. PubMed ID: 3509374
    [No Abstract]   [Full Text] [Related]  

  • 33. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.
    Jones RN; Pfaller MA; Stilwell M;
    Diagn Microbiol Infect Dis; 2001 Feb; 39(2):133-5. PubMed ID: 11248528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria.
    Louie A; Baltch AL; Ritz WJ; Smith RP
    Chemotherapy; 1991; 37(4):275-82. PubMed ID: 1665123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.
    Al-Nawas B; Shah PM
    J Antimicrob Chemother; 1998 Jun; 41(6):655-8. PubMed ID: 9687105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance.
    Schmitz FJ; Higgins PG; Mayer S; Fluit AC; Dalhoff A
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):647-59. PubMed ID: 12373497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.